CPRX – Catalyst Pharmaceuticals, Inc.
Float Short %
7.65
Margin Of Safety %
16
Put/Call OI Ratio
0.56
EPS Next Q Diff
-0.05
EPS Last/This Y
1.12
EPS This/Next Y
0.08
Price
24.42
Target Price
34.86
Analyst Recom
1.14
Performance Q
14.09
Relative Volume
0.66
Beta
0.73
Ticker: CPRX
of 1
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2025-12-26 | CPRX | 24.34 | 0.09 | 0.34 | 4835 |
| 2025-12-29 | CPRX | 24.05 | 0.09 | 0.14 | 4928 |
| 2025-12-30 | CPRX | 23.28 | 0.10 | 0.23 | 5459 |
| 2025-12-31 | CPRX | 23.32 | 0.11 | 0.06 | 5842 |
| 2026-01-02 | CPRX | 23.16 | 0.11 | 4.87 | 6186 |
| 2026-01-05 | CPRX | 22.81 | 0.19 | 0.65 | 6666 |
| 2026-01-06 | CPRX | 22.58 | 0.19 | 0.32 | 6686 |
| 2026-01-07 | CPRX | 22.73 | 0.19 | 0.52 | 6725 |
| 2026-01-08 | CPRX | 22.59 | 0.20 | 0.41 | 6825 |
| 2026-01-09 | CPRX | 22.72 | 0.20 | 0.16 | 6840 |
| 2026-01-12 | CPRX | 23.22 | 0.20 | 1.37 | 7006 |
| 2026-01-13 | CPRX | 22.36 | 0.21 | 7.35 | 7091 |
| 2026-01-14 | CPRX | 23.17 | 0.29 | 0.20 | 7577 |
| 2026-01-15 | CPRX | 22.97 | 0.28 | 0.30 | 7820 |
| 2026-01-16 | CPRX | 22.71 | 0.29 | 0.68 | 8056 |
| 2026-01-20 | CPRX | 23.4 | 0.67 | 0.55 | 4036 |
| 2026-01-21 | CPRX | 24.12 | 0.68 | 0.36 | 4317 |
| 2026-01-22 | CPRX | 24.45 | 0.56 | 0.30 | 5139 |
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2025-12-26 | CPRX | 24.35 | -33.8 | 37.1 | 2.50 |
| 2025-12-29 | CPRX | 24.05 | -33.8 | 33.9 | 2.50 |
| 2025-12-30 | CPRX | 23.28 | -33.8 | 26.2 | 2.50 |
| 2025-12-31 | CPRX | 23.32 | -33.8 | 39.2 | 2.50 |
| 2026-01-02 | CPRX | 23.15 | -33.8 | 35.4 | 2.50 |
| 2026-01-05 | CPRX | 22.81 | -33.8 | 32.8 | 2.50 |
| 2026-01-06 | CPRX | 22.58 | -33.8 | 34.9 | 2.50 |
| 2026-01-07 | CPRX | 22.73 | -33.8 | 41.3 | 2.50 |
| 2026-01-08 | CPRX | 22.59 | -15.0 | 36.5 | 2.50 |
| 2026-01-09 | CPRX | 22.72 | -15.0 | 40.7 | 2.50 |
| 2026-01-12 | CPRX | 23.23 | -15.0 | 47.4 | 2.50 |
| 2026-01-13 | CPRX | 22.36 | -15.0 | 24.3 | 2.50 |
| 2026-01-14 | CPRX | 23.17 | -15.0 | 53.3 | 2.50 |
| 2026-01-15 | CPRX | 22.97 | -15.0 | 35.2 | 2.50 |
| 2026-01-16 | CPRX | 22.70 | -15.0 | 34.3 | 2.50 |
| 2026-01-20 | CPRX | 23.40 | -15.0 | 50.9 | 2.50 |
| 2026-01-21 | CPRX | 24.13 | -15.0 | 51.2 | 2.50 |
| 2026-01-22 | CPRX | 24.42 | -15.0 | 43.3 | 2.50 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2025-12-26 | CPRX | -2.21 | 1.72 | 7.15 |
| 2025-12-29 | CPRX | -2.21 | 1.71 | 7.15 |
| 2025-12-30 | CPRX | -2.21 | 1.71 | 7.15 |
| 2025-12-31 | CPRX | -2.21 | 1.71 | 7.15 |
| 2026-01-02 | CPRX | -2.21 | 1.71 | 7.15 |
| 2026-01-05 | CPRX | -2.21 | 1.57 | 7.15 |
| 2026-01-06 | CPRX | -2.20 | 1.57 | 7.15 |
| 2026-01-07 | CPRX | -2.20 | 1.57 | 7.15 |
| 2026-01-08 | CPRX | -2.20 | 1.57 | 7.15 |
| 2026-01-09 | CPRX | -2.20 | 1.57 | 7.15 |
| 2026-01-12 | CPRX | -2.21 | 1.50 | 7.15 |
| 2026-01-13 | CPRX | -2.20 | 1.50 | 7.65 |
| 2026-01-14 | CPRX | -2.20 | 1.50 | 7.65 |
| 2026-01-15 | CPRX | -2.20 | 1.50 | 7.65 |
| 2026-01-16 | CPRX | -2.20 | 1.50 | 7.65 |
| 2026-01-20 | CPRX | -2.20 | 1.97 | 7.65 |
| 2026-01-21 | CPRX | -2.20 | 1.97 | 7.65 |
| 2026-01-22 | CPRX | -2.20 | 1.97 | 7.65 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
0.64
Avg. EPS Est. Current Quarter
0.46
Avg. EPS Est. Next Quarter
0.59
Insider Transactions
-2.2
Institutional Transactions
1.97
Beta
0.73
Average Sales Estimate Current Quarter
141
Average Sales Estimate Next Quarter
143
Fair Value
28.23
Quality Score
92
Growth Score
99
Sentiment Score
93
Actual DrawDown %
8.1
Max Drawdown 5-Year %
-45.4
Target Price
34.86
P/E
14.27
Forward P/E
13.96
PEG
1.14
P/S
5.2
P/B
3.28
P/Free Cash Flow
12.81
EPS
1.71
Average EPS Est. Cur. Y
2.5
EPS Next Y. (Est.)
2.59
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
37.63
Relative Volume
0.66
Return on Equity vs Sector %
-3.6
Return on Equity vs Industry %
12.3
EPS 1 7Days Diff
0.2
EPS 1 30Days Diff
0.16
EBIT Estimation
43.3
Catalyst Pharmaceuticals, Inc.Sector: Healthcare
Industry: Biotechnology
Employees: 181
Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing medicines for patients living with rare diseases in the United States. It offers Firdapse for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); Fycompa, a novel non-competitive selective antagonist at the postsynaptic ionotropic alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid glutamate receptor that is used to treat focal onset seizures, as well as tonic-clonic seizures; Ruzurgi for the treatment of pediatric LEMS patients; and AGAMREE, a corticosteroid for the treatment of duchenne muscular dystrophy. The company has license agreements with BioMarin Pharmaceutical Inc.; and a collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. Catalyst Pharmaceuticals, Inc. was founded in 2002 and is based in Coral Gables, Florida.
stock quote shares CPRX – Catalyst Pharmaceuticals, Inc. Stock Price stock today
news today CPRX – Catalyst Pharmaceuticals, Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch CPRX – Catalyst Pharmaceuticals, Inc. yahoo finance google finance
stock history CPRX – Catalyst Pharmaceuticals, Inc. invest stock market
stock prices CPRX premarket after hours
ticker CPRX fair value insiders trading